Vaxess Technologies

Vaxess Technologies company information, Employees & Contact Information

Vaxess Technologies is transforming home delivery of next generation therapies. Vaxess's platform combines a proprietary microarray patch and applicator, capable of delivering a wide range of therapies. Advanced biomaterials used for the dissolvable microarray tips enable the greatest levels of dose delivery control, and can be modified to deliver different payloads. Additionally, the patch does not require refrigeration, enabling delivery to low resource settings. Vaxess has raised more than $100 million in grant and venture capital funding from groups such as RA Capital Management, Engine Ventures, GHIC, Mission BioCapital, BARDA, DARPA, NIH, NSF and the Gates Foundation. The company has also generated strong clinical and in-vivo proof of concept in the platform with a wide range of molecules. For more information, please visit the company website at www.vaxess.com or send additional inquiries to contact@vaxess.com.Find more information at www.vaxess.com.

Company Details

Employees
56
Founded
-
Address
127 Western Avenue, Boston,ma 02134,united States
Email
co****@****ess.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
vaxess.com
HQ
Boston, MA
Looking for a particular Vaxess Technologies employee's phone or email?

Vaxess Technologies Questions

News

Vaxess study highlights GLP-1 delivery with microarray patch - Drug Delivery Business

Vaxess study highlights GLP-1 delivery with microarray patch Drug Delivery Business

Vaxess raises $9M to support drug delivery patch, GLP-1 work - Drug Delivery Business

Vaxess raises $9M to support drug delivery patch, GLP-1 work Drug Delivery Business

Vaxess Technologies Announces Grand Opening of GMP Manufacturing Facility - Business Wire

Vaxess Technologies Announces Grand Opening of GMP Manufacturing Facility Business Wire

Vaxess Technologies Receives Grants Totaling $6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella - PR Newswire

Vaxess Technologies Receives Grants Totaling $6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella PR Newswire

Vaxess Raises $10M - citybiz

Vaxess Raises $10M citybiz

Vaxess' flu vaccine patch passes early clinical test, clearing path for further development - Fierce Pharma

Vaxess' flu vaccine patch passes early clinical test, clearing path for further development Fierce Pharma

Vaxess: $12 Million Raised To Develop Shelf-Stable MIMIX Skin Patch For Vaccines And Therapeutics - Pulse 2.0

Vaxess: $12 Million Raised To Develop Shelf-Stable MIMIX Skin Patch For Vaccines And Therapeutics Pulse 2.0

BioProcess Insider Interview: Michael Schrader, Chief Executive Officer and Cofounder, Vaxess Technologies - BioProcess International

BioProcess Insider Interview: Michael Schrader, Chief Executive Officer and Cofounder, Vaxess Technologies BioProcess International

Vaxess Technologies opens GMP facility for vaccine patch clinical trials - Cleanroom Technology

Vaxess Technologies opens GMP facility for vaccine patch clinical trials Cleanroom Technology

Woburn biotech takes needles out of GLP-1 delivery with patch - The Business Journals

Woburn biotech takes needles out of GLP-1 delivery with patch The Business Journals

Vaxess patches $8.2m series A - - Global Venturing

Vaxess patches $8.2m series A - Global Venturing

Biotech company seeks to overcome hurdles to develop flu vaccine skin patch - statnews.com

Biotech company seeks to overcome hurdles to develop flu vaccine skin patch statnews.com

Vaxess Announces Federal Contract for Development of the MIMIX Smart Release Patch Platform - Business Wire

Vaxess Announces Federal Contract for Development of the MIMIX Smart Release Patch Platform Business Wire

Vaxess Technologies: Developing Vaccine Patches To Disrupt Multiple Billion-Dollar Markets - Pulse 2.0

Vaxess Technologies: Developing Vaccine Patches To Disrupt Multiple Billion-Dollar Markets Pulse 2.0

Vaccine patch maker Vaxess raises $12M, names new CEO - Drug Delivery Business

Vaccine patch maker Vaxess raises $12M, names new CEO Drug Delivery Business

Aimed at Increasing Vaccine Access, Vaxess Raises the First Part of a $3.75M Series A - The Business Journals

Aimed at Increasing Vaccine Access, Vaxess Raises the First Part of a $3.75M Series A The Business Journals

Top Vaxess Technologies Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant